文献速递血栓与止血

补体调节因子H增强抗体保护人内皮细胞免受aHUS血清补体攻击

Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera.
PubMed 文献 · Blood Adv · 2019-01-01

研究鉴定了一种抗补体调节因子H(FH)单克隆抗体,可增强FH介导的原代人内皮细胞补体保护,同时保留补体对细菌的杀伤作用;该抗体还能恢复携带多种FH杂合突变的aHUS患者血清中的补体调节功能。数据提示FH通常以较低活性构象循环,可被抗体增强活性,从而在不干扰抗菌防御的前提下抑制人细胞上不需要的补体激活。

要点

  • 抗FH单克隆抗体增强FH介导的内皮细胞补体保护,同时保留补体杀菌活性。
  • 该抗体可恢复携带多种FH杂合突变的aHUS患者血清中的补体调节。
  • 数据提示FH通常以较低活性构象循环,可被增强为更高活性状态。

核心结论

  • 抗体介导的FH增强可能成为抑制人细胞上不需要的补体激活的高效方法,同时保留补体对病原体的保护作用。

研究设计与样本

  • 研究鉴定了一种抗FH单克隆抗体,并在原代人内皮细胞及携带多种FH杂合突变的aHUS患者血清中评价其作用。

主要发现

  • 该抗FH单克隆抗体诱导FH介导的原代人内皮细胞补体保护增强,同时保留补体介导的细菌杀伤。
  • 该FH激活抗体恢复了携带多种已知损害FH功能并失调补体激活的FH杂合突变aHUS患者血清中的补体调节。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mutations in the gene encoding for complement regulator factor H (FH) severely disrupt its normal function to protect human cells from unwanted complement activation, resulting in diseases such as atypical hemolytic uremic syndrome (aHUS). aHUS presents with severe hemolytic anemia, thrombocytopenia, and renal disease, leading to end-stage renal failure. Treatment of severe complement-mediated disease, such as aHUS, by inhibiting the terminal complement pathway, has proven to be successful but at the same time fails to preserve the protective role of complement against pathogens. To improve complement regulation on human cells without interfering with antimicrobial activity, we identified an anti-FH monoclonal antibody (mAb) that induced increased FH-mediated protection of primary human endothelial cells from complement, while preserving the complement-mediated killing of bacteria. Moreover, this FH-activating mAb restored complement regulation in sera from aHUS patients carrying various heterozygous mutations in FH known to impair FH function and dysregulate complement activation. Our data suggest that FH normally circulates in a less active conformation and can become more active, allowing enhanced complement regulation on human cells. Antibody-mediated potentiation of FH may serve as a highly effective approach to inhibit unwanted complement activation on human cells in a wide range of hematological diseases while preserving the protective role of complement against pathogens.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Pouw RB, Brouwer MC, de Gast M, et al. Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera. Blood Adv. 2019. PMID: 30804016. doi:10.1182/bloodadvances.2018025692

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。